eravacycline
Sign in to saveEravacycline (TP-434, Xerava) is a synthetic halogenated tetracycline class antibiotic by Tetraphase Pharmaceuticals. It is closely related to tigecycline. It has a broad spectrum of activity including many multi-drug resistant strains of bacteria. Phase III studies in complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI) were recently completed with mixed results. Eravacycline was granted fast track designation by the FDA and is currently available in USA.
Wikidata facts
- Mass
- 558.2125921719999
Show 4 more facts
- chemical formula
- C₂₇H₃₁FN₄O₈
- isomeric SMILES
- CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=C(C(=C4C(=O)C3=C([C@@]2(C(=O)C(=C1O)C(=O)N)O)O)O)NC(=O)CN5CCCC5)F
- Commons category
- Eravacycline
- canonical SMILES
- CN(C)C1C(O)=C(C(N)=O)C(=O)C2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4CC3CC12
Sources (2)
via Wikidata · CC0
~7 min read
Article
13 sectionsContents
- Medical uses
- Spectrum of activity
- Gram-positive organisms
- Gram-negative organisms
- Clinical trials
- Phase 3 trials
- Complicated Intra-abdominal infections (IGNITE 1)
- Complicated Intra-abdominal Infections (IGNITE 4)
- Complicated Urinary Tract infections (IGNITE 2)
- Complicated Urinary Tract Infections (IGNITE 3)
- Commercial information
- References
- External links
Eravacycline (TP-434, Xerava) is a synthetic halogenated tetracycline class antibiotic by Tetraphase Pharmaceuticals. It is closely related to tigecycline. It has a broad spectrum of activity including many multi-drug resistant strains of bacteria. Phase III studies in complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI) were recently completed with mixed results. Eravacycline was granted fast track designation by the FDA and is currently available in USA.
== Medical uses == Eravacycline has shown broad spectrum of activity against a variety of Gram-positive and Gram-negative bacteria, including multi-drug resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae. It is currently being formulated as for intravenous and oral administration.